NuVasive upgraded to Outperform from Market Perform at Leerink Leerink upgraded NuVasive citing the company's improved operational performance and upside to consensus estimates. The firm raised its price target for shares to $45 from $33.
NuVasive CEO news an incremental positive, says Piper Jaffray Piper Jaffray views NuVasive's naming Greg Lucier as its permanent CEO as an incremental positive despite the executive's lack direct experience in the spine industry. Piper notes its channel checks indicate no meaningful sales force disruption from the CEO transition. It reiterates an Overweight rating on NuVasive with a $56 price target.